Press Releases Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
5.1 ^USD	-1.35%		+3.87%	-43.27%

02/05	Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024
02/05	Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aurinia: Q1 Earnings Snapshot	02/05	AQ
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results	02/05	BU
AURINIA PHARMACEUTICALS - THE U.S. FOOD & DRUG ADMINISTRATION APPROVES UPDATED LUPKYNIS LABEL TO INCLUDE LONG-TERM DATA FROM THE AURORA CLINICAL PROGRAM	01/05	AQ
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month	01/05	BU
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program	30/04	BU
UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE	17/04	AQ
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	16/04	BU
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	15/04	BU
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04	BU
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	29/02	BU
Aurinia to Participate in Upcoming Investor Healthcare Conferences	27/02	BU
Aurinia: Q4 Earnings Snapshot	15/02	AQ
Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value	15/02	BU
Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024	05/02	BU
Life Sciences Ontario Announces Recipients of 2024 LSO Awards	16/01	AQ
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results	05/01	BU
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200	20/12	BU
AURINIA PHARMACEUTICALS ANNOUNCES COLLABORATION PARTNER OTSUKA FILED NEW DRUG APPLICATION FOR LUPKYNIS IN JAPAN	14/11	AQ
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan	13/11	BU
Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNISⓇ (voclosporin) for Patients with Lupus Nephritis at ACR 2023	07/11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Press Releases

Filters